tirzepatide surpass cvot Comparison of and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics Tirzepatide Outperforms Dulaglutide in Slashing

Jan-Roblero and Cruz-Maya, 2023)

Many women resume Ozempic post-partum for continued PCOS management

Clinical trials in a dish: a perspective on the coming revolution in drug development

PlexusDx patients can ask their healthcare provider which specific probiotic brands have the strongest evidence base for supporting GLP-1 therapy adaptation

The Longevity Seeker For those who are proactive about their health and want to prevent decline before it starts, MOTS-c serves as a foundational therapy for cellular maintenance and protection

Treatment with RYBELSUS 14 mg once daily for 26 weeks resulted in non-inferior reductions in HbA1c compared to liraglutide 1.8 mg (see Table 7)